<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PRF</journal-id>
<journal-id journal-id-type="hwp">spprf</journal-id>
<journal-id journal-id-type="nlm-ta">Perfusion</journal-id>
<journal-title>Perfusion</journal-title>
<issn pub-type="ppub">0267-6591</issn>
<issn pub-type="epub">1477-111X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0267659112469641</article-id>
<article-id pub-id-type="publisher-id">10.1177_0267659112469641</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Wet-priming extracorporeal membrane oxygenation device maintains sterility for up to 35 days of follow-up</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Naso</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff1-0267659112469641">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gandaglia</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0267659112469641">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Balboni</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff2-0267659112469641">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zanella</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff3-0267659112469641">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Danesin</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff4-0267659112469641">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Spina</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff5-0267659112469641">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gerosa</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff1-0267659112469641">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0267659112469641">
<label>1</label>Department of Cardiac, Thoracic and Vascular Science, University of Padova, Italy</aff>
<aff id="aff2-0267659112469641">
<label>2</label>Sorin Group Italia, Mirandola, Italy</aff>
<aff id="aff3-0267659112469641">
<label>3</label>Coordinator of Perfusionist Staff, Padova Hospital, Italy</aff>
<aff id="aff4-0267659112469641">
<label>4</label>Department of Chemical Process Engineering, University of Padova, Italy</aff>
<aff id="aff5-0267659112469641">
<label>5</label>Department of Experimental Biomedical Science, University of Padova, Italy</aff>
<author-notes>
<corresp id="corresp1-0267659112469641">Filippo Naso Department of Cardiac, Thoracic and Vascular Science University of Padova, Italy Via Giustiniani 2 35128 Padova Italy Email: <email>fnaso@bio.unipd.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>3</issue>
<fpage>208</fpage>
<lpage>213</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>In emergency cases, rapid extracorporeal membrane oxygenation (ECMO) device initialization is able to drastically reduce the incidence of patient morbidity and/or mortality. Pre-assembled and ready-to-use ECMO circuits might save up to 30-60 critical minutes in patient management.</p>
<p>Six ECMO circuits (Oxygenator D905 EOS with REVOLUTION™ pump and Sorin PTS) were assembled in the operating room in standard conditions and then placed at 37°C for 35 days in order to evaluate possible contamination and ingrowth of micro-organisms. Every 7 days after ECMO circuit assembly and wet-priming, samples of priming fluid were analyzed to verify the presence/absence of possible common contaminants (<italic>Enterobacteriaceae, Staphylococcus aureus</italic> and fungi). Moreover, two supplementary circuits, used as positive controls, were deliberately inoculated with a known concentration of a <italic>Escherichia coli</italic> strain and prime samplings carried out at different time-points to determine bacterial growth rate.</p>
<p>Sterility was maintained in the ECMO circuits for up to 35 days.</p>
</abstract>
<kwd-group>
<kwd>extracorporeal membrane oxygenation (ECMO)</kwd>
<kwd>cardiopulmonary bypass (CPB)</kwd>
<kwd>CPB equipment</kwd>
<kwd>emergency</kwd>
<kwd>surgical equipment</kwd>
<kwd>critical care management</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0267659112469641" sec-type="intro">
<title>Introduction</title>
<p>Extracorporeal membrane oxygenation (ECMO) consists of a modified cardiopulmonary bypass circuit (CPB) able to provide both gas exchange and systemic perfusion, sustaining a patient’s life when the native cardiac or lung functions are subjected to a reversible failure.<sup><xref ref-type="bibr" rid="bibr1-0267659112469641">1</xref></sup> More recently, this device has been utilized as a resuscitation tool for the management of acute cardiac support during cardiac arrest.<sup><xref ref-type="bibr" rid="bibr2-0267659112469641">2</xref></sup> Since ECMO was first successfully applied, both to adults in 1972 and neonatal patients in 1976,<sup><xref ref-type="bibr" rid="bibr3-0267659112469641">3</xref>,<xref ref-type="bibr" rid="bibr4-0267659112469641">4</xref></sup> advances in the design of circuit components (particularly the oxygenator) have improved the ease of use and, hence, the diffusion of this technology.</p>
<p>New oxygenators are associated with reduced red blood cell and platelet transfusion requirements and with improved gas exchange performance when compared to those previously available.<sup><xref ref-type="bibr" rid="bibr5-0267659112469641">5</xref></sup> Furthermore, centrifugal pumps have been improved, with low haemolysis rates, while coating of all circuit components enhances biocompatibility. All these new features allow short periods of ECMO support with no need for anticoagulation therapy, thus, facilitating the management of clinical occurrences where high bleeding risks are present.<sup><xref ref-type="bibr" rid="bibr6-0267659112469641">6</xref></sup></p>
<p>Currently, ECMO support time for an adult patient frequently exceeds 21 days<sup><xref ref-type="bibr" rid="bibr7-0267659112469641">7</xref></sup> and can last up to 107 days, mostly when ECMO is applied as bridge to lung transplantation.<sup><xref ref-type="bibr" rid="bibr8-0267659112469641">8</xref></sup></p>
<p>The multicentre, randomised CESAR clinical trial, beginning in 2009, compared the efficacy and the economic burden of conventional ventilatory support (e.g. steroids, prone positioning, bronchoscopy and inhaled nitric oxide) vs. ECMO, confirming the improvement in safety, clinical efficacy and cost-effectiveness of the latter. Moreover, the transfer of all adult patients with severe, but potentially reversible, respiratory failure to a centre with an ECMO-based management protocol is strongly recommended for significantly improved survival without incurring severe disabilities.<sup><xref ref-type="bibr" rid="bibr9-0267659112469641">9</xref></sup></p>
<p>In cases of emergency, immediate ECMO initialization is able to drastically reduce the incidence of morbidity and mortality in the patients, avoiding the onset of adverse neurological sequelae.<sup><xref ref-type="bibr" rid="bibr10-0267659112469641">10</xref></sup> However, before connecting the patient to an ECMO device, perfusionists must aseptically assemble, prime and de-air the extracorporeal circuit (ECC) as quickly as possible. Thus, prompt availability of a previously assembled sterile ECC could be of critical importance in saving time.</p>
<p>Many institutions have adopted the policy of having an ECC assembled in advance, especially during the weekend;<sup><xref ref-type="bibr" rid="bibr11-0267659112469641">11</xref>,<xref ref-type="bibr" rid="bibr12-0267659112469641">12</xref></sup> nevertheless, it may happen that the circuit is not used. The official regulations in the management of sterile devices require their immediate use after opening the sterile packaging. No further information is available regarding the range of time during which an ECC is expected to remain sterile after the tubing has been connected and the circuit filled with prime. Each ready-to-use, but unused, device results in an economic loss of approximately 2,000 - 5,000 euros (depending on the manufacturer).</p>
<p>From 1972 to date, only six investigations have been published in the literature reporting the maintenance of sterility for ECMO circuits up to two weeks.<sup><xref ref-type="bibr" rid="bibr11-0267659112469641">11</xref>
<xref ref-type="bibr" rid="bibr12-0267659112469641"/><xref ref-type="bibr" rid="bibr13-0267659112469641"/><xref ref-type="bibr" rid="bibr14-0267659112469641"/><xref ref-type="bibr" rid="bibr15-0267659112469641"/>-<xref ref-type="bibr" rid="bibr16-0267659112469641">16</xref></sup> In 2007, Alsoufi and colleagues reported the maintenance of sterility in primed ECMO circuits for 30 days, even if the results of aerobic, anaerobic and fungus cultures were not shown.<sup><xref ref-type="bibr" rid="bibr17-0267659112469641">17</xref></sup></p>
<p>In order to extend the possible lifespan of a primed ECMO device, we have investigated the maintenance of sterility of six assembled and primed circuits during an operational time of 35 days at 37°C. Additionally, a bacterial broth of <italic>Escherichia coli</italic> was added in two supplementary recirculating ECMO circuits in order to evaluate the pattern of contamination and growth of the micro-organism at 37°C.</p>
</sec>
<sec id="section2-0267659112469641" sec-type="methods">
<title>Methods</title>
<sec id="section3-0267659112469641">
<title>Circuit assembly</title>
<p>Eight innovative ECMO circuits (<xref ref-type="table" rid="table1-0267659112469641">Table 1</xref>) were assembled and primed under sterile conditions in the cardiac surgery operating room at Padova Hospital by certified perfusionists. Each circuit was primed with 1.5 litres of standard electrolyte solution pH 7.4, with sodium gluconate (Fresenius Kabi, Verona, Italy). After filling all the circuit components (tubing and oxygenator), the excess of primed solution was collected in a reservoir bag (approximately 1.0 L). The bag was used to ensure the presence of an adequate volume of recirculating priming fluid, notwithstanding the numerous samples taken for the investigation. Subsequently, the circuits were divided into three groups as follows:</p>
<table-wrap id="table1-0267659112469641" position="float">
<label>Table 1.</label>
<caption>
<p>Technical features of the tested ECMO circuits.</p></caption>
<graphic alternate-form-of="table1-0267659112469641" xlink:href="10.1177_0267659112469641-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Circuit Component</th>
<th align="left" colspan="2">Technical Features</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="9" valign="top"><bold>Oxygenator D905 EOS ECMO</bold>
<break/>Dideco ECMO Oxygenator Family
<break/>Sorin Group Italy</td>
<td>Recommended maximum blood flow (ml/min)</td>
<td>5000</td>
</tr>
<tr>
<td>Static volume (oxy module+HE) (ml)</td>
<td>150</td>
</tr>
<tr>
<td>Membrane surface area (sq.m)</td>
<td>1.2</td>
</tr>
<tr>
<td>Membrane type</td>
<td>HOLLOW FIBRE</td>
</tr>
<tr>
<td>Membrane material</td>
<td>POLYMETHYLPENTENE</td>
</tr>
<tr>
<td>Heat exchanger surface area (sq.m)</td>
<td>0.14</td>
</tr>
<tr>
<td rowspan="3">Connections</td>
<td>3/8’’ VENOUS INLET</td>
</tr>
<tr>
<td>3/8’’ ARTERIAL OUTLET</td>
</tr>
<tr>
<td>1/4’’ RECIRCULATION/PURGING LINE</td>
</tr>
<tr>
<td rowspan="8" valign="top"><bold>REVOLUTION™ pump</bold>
<break/>Centrifugal Blood Pump
<break/>Sorin Group Italy</td>
<td>Priming Volume (ml)</td>
<td>57</td>
</tr>
<tr>
<td>Maximum Flow Rate (lpm)</td>
<td>8</td>
</tr>
<tr>
<td>Maximum Outlet Pressure (mm Hg)</td>
<td>800</td>
</tr>
<tr>
<td>Pump casing material</td>
<td>POLYCARBONATE</td>
</tr>
<tr>
<td>Shaft material</td>
<td>STAINLESS STEEL</td>
</tr>
<tr>
<td>Impeller &amp; Magnet Housing material</td>
<td>ABS</td>
</tr>
<tr>
<td>Bearings material</td>
<td>HDPE</td>
</tr>
<tr>
<td>Magnet material</td>
<td>NYLON NdFeB Blend</td>
</tr>
<tr>
<td/>
<td>Connections</td>
<td>3/8’’ INLET / OUTLET PORT</td>
</tr>
<tr>
<td align="center" colspan="3">The tubing system consist of PVC tubing of Sorin Group Perfusion Tubing Systems (PTS)</td>
</tr>
</tbody>
</table></table-wrap>
<p>-R circuits (n=3), represented by the ECMO circuit coupled to a Stöckert Centrifugal Pump Console (SCPC, Sorin Group Gmbh, Munich, Germany). The prime was circulated with a flow of 0.5 L/minute at 37°C for 35 days. Every 7 days, a sterile withdrawal of an aliquot of the prime was taken to investigate possible contamination by <italic>Enterobacteriaceae, Staphylococcus aureus</italic> and fungi (both moulds and yeasts).</p>
<p>-NR circuits (n=3) were placed at 37°C for 35 days in conditions of non-circulating prime. Every 7 days, a sterile withdrawal of the prime was performed. Before each sampling, the prime was circulated for 15 minutes.</p>
<p>-P circuits (n=2, P1 and P2) featured prime inoculated with a 5 ml suspension of 7.6 x 105 UFC/ml (unit forming colony) of <italic>E. coli</italic>. Subsequently, the ECMO circuits were coupled with a Stöckert Centrifugal Pump Console at a constant flow of 0.5 L/minute at 37°C for 24 days and 21 days for P1 and P2, respectively. At different time-points of 3, 6, 19, 21 and 24 days, a sterile withdrawal of prime was made and the concentration of <italic>E. coli</italic> (UFC/ml) determined by visual counting.</p>
<p>For each ECMO system, the oxygenator gas port was been left open, exposing the primed circuits to the atmospheric air present in the room where the ECMO circuits were incubated. However, to safeguard from external contamination, a 0.22 µm filter was inserted, permitting the development of the micro-organism (in R and NR circuits) only if they are introduced during the filling of the tubes with the primed solution.</p>
<p>All the circuits were incubated in a hot-room (constant 37°C) open to the passage of all personnel of the laboratory during the observation period, even if the circuits had never been moved or handled except for the samples needed for the assessment of the contamination (R and NR circuits) or the bacterial growth curve (P circuits).</p>
</sec>
<sec id="section4-0267659112469641">
<title>Qualitative contamination investigation</title>
<p>Every 7 days, 25 ml of prime solution were harvested from each R and NR circuits in sterile conditions. After checking the pH, the total volume of each sample was divided as follows: 10 ml were discarded to eliminate the dead volume in the tubing system; 5 ml was placed in Levine EMB Agar culture medium (BD Diagnostics, Sparks, MD, USA) to detect the possible presence of enterobacter; 5 ml was placed in CHROMagar™ Staph aureus culture medium (BD Diagnostics) for <italic>Staphylococcous aureus</italic> detection; 5 ml was placed in Sabouraud Glucose Agar culture medium (BD Diagnostics) to test for fungal contamination. All the cultures were then incubated at 37°C for 48 hours.</p>
<p>In the case of positivity for Levine EMB Agar, a BBL Enterotube II (BD Diagnostics) was used to identify the contaminating <italic>Enterobacteriaceae</italic> strain.</p>
</sec>
<sec id="section5-0267659112469641">
<title>Quantitative determination of Escherichia coli in deliberately contaminated ECMO circuits</title>
<p>Before inoculating <italic>E. coli</italic> at a known concentration in the P circuits, 1 ml of bacteria broth solution was seeded in Levine EMB Agar (BD Diagnostics) for 48 hours at 37°C. Subsequently, the strain was identified using the BBL Enterotube II in order to verify, for subsequent samples, the quality of possible contamination.</p>
<p>At 3, 6, 19, 21 and 24 days, 25 ml of prime was harvested from the P1 and P2 circuits in sterile condition and scale diluted at concentrations of 1:10, 1:100 and 1:1000 in Luria Bertani culture medium (BD Diagnostics). Following this, 5 ml of diluted sample was placed in different plates containing Levine EMB medium and incubated for 24 hours at 37°C.</p>
<p>The UFC bacterial counting relied on visual detection. For each plate, a colony was examined for strain identification by BBL Enterotube II.</p>
</sec></sec>
<sec id="section6-0267659112469641" sec-type="results">
<title>Results</title>
<p>ECMO circuit (n=6) testing for microbiological contamination after standard manual assembly demonstrated the ability to maintain sterility for up to 35 days at 37°C (<xref ref-type="table" rid="table2-0267659112469641">Table 2</xref>, <xref ref-type="table" rid="table3-0267659112469641">Table 3</xref>). There was no difference between the circulating (R1-R2-R3; <xref ref-type="table" rid="table2-0267659112469641">Table 2</xref>) and non-circulating circuits (NR1-NR2-NR3; <xref ref-type="table" rid="table3-0267659112469641">Table 3</xref>). No turbidity of the priming solution in any analyzed circuit was found.</p>
<table-wrap id="table2-0267659112469641" position="float">
<label>Table 2.</label>
<caption><p>Recirculating circuits (R1-R2-R3) investigated after 35 days of operation at 37°C. The sampling was performed every 7 days and cultured on Levine EMB Agar (L-EMB-A), CHROMagar™ Staph aureus (C-Staph aureus) and Sabouraud Glucose Agar (S-Glucose-A) for 48 hours at 37°C.</p></caption>
<graphic alternate-form-of="table2-0267659112469641" xlink:href="10.1177_0267659112469641-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="5">-------- R1 ECMO Circuit --------</th>
<th align="center" colspan="5">------ R2 ECMO Circuit ------</th>
<th align="center" colspan="5">------- R3 ECMO Circuit -------</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>DAYS</bold></td>
<td>7</td>
<td>14</td>
<td>21</td>
<td>28</td>
<td>35</td>
<td>7</td>
<td>14</td>
<td>21</td>
<td>28</td>
<td>35</td>
<td>7</td>
<td>14</td>
<td>21</td>
<td>28</td>
<td>35</td>
</tr>
<tr>
<td><bold>pH</bold></td>
<td>6</td>
<td>6</td>
<td>5.5</td>
<td>5.5</td>
<td>5.5</td>
<td>7</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td><bold>L-EMB-A</bold></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td><bold>C-Staph aureus</bold></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td><bold>S-Glucose-A</bold></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0267659112469641"><p>N = negative.</p></fn>
</table-wrap-foot></table-wrap>
<table-wrap id="table3-0267659112469641" position="float">
<label>Table 3.</label>
<caption>
<p>Non-recirculating circuits (NR1-NR2-NR3) investigated after 35 days at 37°C. The sampling was performed every 7 days and cultured on Levine EMB Agar (L-EMB-A), CHROMagar™ Staph aureus (C-Staph aureus) and Sabouraud Glucose Agar (S-Glucose-A) for 48 hours at 37°C.</p>
</caption>
<graphic alternate-form-of="table3-0267659112469641" xlink:href="10.1177_0267659112469641-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="5">-- NR1 ECMO Circuit --</th>
<th align="center" colspan="5">-- NR2 ECMO Circuit --</th>
<th align="center" colspan="5">-- NR3 ECMO Circuit --</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>DAYS</bold></td>
<td>7</td>
<td>14</td>
<td>21</td>
<td>28</td>
<td>35</td>
<td>7</td>
<td>14</td>
<td>21</td>
<td>28</td>
<td>35</td>
<td>7</td>
<td>14</td>
<td>21</td>
<td>28</td>
<td>35</td>
</tr>
<tr>
<td><bold>pH</bold></td>
<td>7</td>
<td>7</td>
<td>6</td>
<td>6</td>
<td>5.5</td>
<td>7</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>5.5</td>
<td>5.5</td>
</tr>
<tr>
<td><bold>L-EMB-A</bold></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td><bold>C-Staph aureus</bold></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td><bold>S-Glucose-A</bold></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0267659112469641"><p>N=negative.</p></fn>
</table-wrap-foot></table-wrap>
<p>The final pH measurement was not significantly different between the R group (6.3 ± 0.7, n=15) and the NR group (6.3 ± 0.6, n=15): pH value decreased over follow-up time from 7.4 ± 0.3 to 6.3 ± 0.65 after 35 days.</p>
<p>The circulating circuits (P1 and P2) deliberately contaminated with a strain of <italic>E. coli</italic> showed the maintenance of variable and non-negligible viable bacteria quantities from the inoculation time until operational day 21<sup>st</sup> – 24<sup>th</sup> (<xref ref-type="fig" rid="fig1-0267659112469641">Figure 1</xref>). The BBL Enterotube II analysis, conducted for each sampling from the P1 and P2 circuits, demonstrated the presence in the priming solution of the same bacterial strain originally inoculated, with no contamination with other strain types.</p>
<fig id="fig1-0267659112469641" position="float">
<label>Figure 1.</label>
<caption>
<p>Growth curve for <italic>Escherichia coli</italic> expressed as UFC/ml x10<sup>5</sup>, inoculated in the re-circulating P1 and P2 ECMO circuits. After 24 (P1) and 21 days (P2) from the inoculation, bacteria have not been detected.</p>
</caption>
<graphic xlink:href="10.1177_0267659112469641-fig1.tif"/></fig>
</sec>
<sec id="section7-0267659112469641" sec-type="discussion">
<title>Discussion</title>
<p>During ECMO assembly, contamination of the circuits by bacteria or micro-organisms originally present on operator’s skin and breath or in the air of the operating theatre can occur. Almost 50% of human skin microbial flora is constituted by <italic>Staphylococcus aureus</italic><sup><xref ref-type="bibr" rid="bibr18-0267659112469641">18</xref></sup> while fungi <italic>sporae</italic> can be transported in the air (i.e. they may be present in the filter of air conditioning systems) and can deposit themselves onto clothes such as surgical gowns. Finally, <italic>E. coli</italic> can be easily used as a micro-organism model whose presence is able to provide a standard index of contamination. For this reason, we aimed this study to the detection of such micro-organisms in primed ECMO circuits and to determine the safe time-frame period of sterility preservation. In all cases (R, NR and P circuits), conditions facilitating bacterial growth were adopted (37°C).</p>
<p>In 1990, Chorack and colleagues<sup><xref ref-type="bibr" rid="bibr11-0267659112469641">11</xref></sup> demonstrated that an ECC circuit, assembled without priming, could maintain sterility for 48-60 hours. Omishak et al.<sup><xref ref-type="bibr" rid="bibr13-0267659112469641">13</xref></sup> raised the threshold to 2.5 days using complete ECMO circuits (n=17) primed (but not circulating) with three litres of solution. Contamination analyses were conducted by filtering one litre of the total prime volume for each circuit and, afterwards, placing the filter in culture broth. Similar results were obtained again, in 1998, by Lonsky et al.<sup><xref ref-type="bibr" rid="bibr15-0267659112469641">15</xref></sup></p>
<p>Young and colleagues, in 1997,<sup><xref ref-type="bibr" rid="bibr14-0267659112469641">14</xref></sup> confirmed the possibility of maintaining the sterile condition of ECC circuits up to 7 days, with (n=6) or without (n=6) priming, even if the primed circuit was not circulating. The presence of microbiological contamination was detected by using cotton swab sampling. Searles et al., in 1999,<sup><xref ref-type="bibr" rid="bibr12-0267659112469641">12</xref></sup> assembled, primed (with 3.0 – 4.0 L of solution) and cultured 43 circulating ECC circuits, confirming the sterility up to 3 days. Finally, in 2005, Karimova and colleagues demonstrated that circulating ECMO circuits remain sterile up to a maximum of 2 weeks.<sup><xref ref-type="bibr" rid="bibr16-0267659112469641">16</xref></sup></p>
<p>Our research study exhibits that, with currently available devices, a pre-assembled ECMO circuit can be safely maintained sterile up to 35 days. There was no evidence of contamination in any of the six analyzed circuits; worthy of note is the fact that it was demonstrated in the circuits where the prime was not circulating (NR group, n=3), the presence of a static filled solution, without an active flow, does not in any way affect the onset of bacterial growth. On the contrary, in the event of contamination (P circuits, n=2), bacteria were able to grow and maintain viability in ECMO circulating circuits for a maximum time of 24 days.</p>
<p>With reference to the literature in which the use of large volumes of priming solution forces a withdrawal of considerable quantities for the microbiological assays, the oxygenator used in this study made it possible to reduce the prime volume (including the reservoir volume) to just 1.0 – 1.5 L, allowing the carrying out of representative analysis with small sampling quantities (15 ml). This interesting feature was confirmed by the presence of bacterial growth in the positive controls (<xref ref-type="fig" rid="fig1-0267659112469641">Figure 1</xref>).</p>
<p>The slight acidification of the primed solution exhibited after 35 days of investigation is probably attributable to the release of phthalate from the tubes. In fact, phthalates or phthalate esters (esters of phthalic acid) are mainly used as plasticizers (substances added to plastics to increase their flexibility, transparency, durability, and longevity). They are aimed primarily at softening polyvinyl chloride (PVC). Several studies have found evidence of their release during the use of devices such as ECMO circuits,<sup><xref ref-type="bibr" rid="bibr19-0267659112469641">19</xref>
<xref ref-type="bibr" rid="bibr20-0267659112469641"/>-<xref ref-type="bibr" rid="bibr21-0267659112469641">21</xref></sup> increased by long periods of exposition at temperature such as 37°C.<sup><xref ref-type="bibr" rid="bibr22-0267659112469641">22</xref></sup> The amount of phthalates which may be released is directly related and vary for each tube and this could explain the different decreases in pH of circuits R1, R2, NR1, NR2 and NR3, with the only exception of the R3 circuit. However, this aspect is actually under investigation.</p>
<p>Moreover, all circuit components are Ph.i.s.i.o.<sup>®</sup> technology treated (based on a coating of Phosphorylcholine molecules); such treatment is able to improve platelet preservation, reduce coagulation factor activation and inflammatory reactions and, consequently, limit postoperative blood loss. The coating is not removed, either by the priming solution or by blood flow during CPB, thus, ensuring a high degree of effectiveness and durability (data not shown).</p>
<p>In conclusion, preservation of sterility up to 35 days has no meaning if the utmost attention is not paid when assembling and priming the circuit. In fact, contamination of the circuit, even if unintended, leads to the proliferation of infection sources which can be potentially active for over 20 days, depending on the initial bacteria concentration.</p>
<p>According to our data, the possibility of pre- assembling an ECMO circuit in advance appears to be safe in granting the opportunity of time-saving in emergency situations. However, the perfusionist’s ability and attention in adopting aseptic techniques is mandatory in order to avoid contamination.</p>
</sec>
</body>
<back>
<ack><p>We thank Sorin Group’s Cardiopulmonary Business for donations of the equipment necessary to collect data for this study.</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<label>Conflicts of interest statement</label>
<p>The authors declare that there are no conflicts of interest.</p></fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The project is supported by Fondazione Cassa di Risparmio di Padova e Rovigo (Italian Heart Project).</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0267659112469641">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>PK</given-names></name>
<name><surname>Napolitano</surname><given-names>LM</given-names></name>
<name><surname>Bartlett</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Extracorporeal membrane oxygenation in adult acute respiratory distress syndrome</article-title>. <source>Crit Care Clin</source> <year>2011</year>; <volume>27</volume>: <fpage>627</fpage>–<lpage>646</lpage>.</citation>
</ref>
<ref id="bibr2-0267659112469641">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maclaren</surname><given-names>G</given-names></name>
<name><surname>Butt</surname><given-names>W</given-names></name>
</person-group>. <article-title>Extracorporeal membrane oxygenation and sepsis</article-title>. <source>Crit Care Resusc</source> <year>2007</year>; <volume>9</volume>: <fpage>76</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr3-0267659112469641">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartlett</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Extracorporeal life support: history and new directions</article-title>. <source>ASAIO J</source> <year>2005</year>; <volume>51</volume>: <fpage>487</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr4-0267659112469641">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mielck</surname><given-names>F</given-names></name>
<name><surname>Quintel</surname><given-names>M</given-names></name>
</person-group>. <article-title>Extracorporeal membrane oxygenation</article-title>. <source>Curr Opin Crit Care</source> <year>2005</year>; <volume>11</volume>: <fpage>87</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr5-0267659112469641">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peek</surname><given-names>GJ</given-names></name>
<name><surname>Killer</surname><given-names>HM</given-names></name>
<name><surname>Reeves</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Early experience with a polymethyl pentene oxygenator for adult extracorporeal life support</article-title>. <source>ASAIO J</source> <year>2002</year>; <volume>48</volume>: <fpage>480</fpage>–<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr6-0267659112469641">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mangoush</surname><given-names>O</given-names></name>
<name><surname>Purkayastha</surname><given-names>S</given-names></name>
<name><surname>Haj-Yahia</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes</article-title>. <source>Eur J Cardiothorac Surg</source> <year>2007</year>; <volume>31</volume>: <fpage>1058</fpage>–<lpage>1069</lpage>.</citation>
</ref>
<ref id="bibr7-0267659112469641">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camboni</surname><given-names>D</given-names></name>
<name><surname>Philipp</surname><given-names>A</given-names></name>
<name><surname>Lubnow</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Support time-dependent outcome analysis for veno-venous extracorporeal membrane oxygenation</article-title>. <source>Eur J Cardiothorac Surg</source> <year>2011</year>; <volume>40</volume>: <fpage>1341</fpage>–<lpage>1346</lpage>.</citation>
</ref>
<ref id="bibr8-0267659112469641">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iacono</surname><given-names>A</given-names></name>
<name><surname>Groves</surname><given-names>S</given-names></name>
<name><surname>Garcia</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Lung transplantation following 107 days of extracorporeal membrane oxygenation</article-title>. <source>Eur J Cardiothorac Surg</source> <year>2010</year>; <volume>37</volume>: <fpage>969</fpage>–<lpage>971</lpage>.</citation>
</ref>
<ref id="bibr9-0267659112469641">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peek</surname><given-names>GJ</given-names></name>
<name><surname>Mugford</surname><given-names>M</given-names></name>
<name><surname>Tiruvoipati</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial</article-title>. <source>Lancet</source> <year>2009</year>; <volume>374</volume>: <fpage>1351</fpage>–<lpage>1363</lpage>.</citation>
</ref>
<ref id="bibr10-0267659112469641">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hamrick</surname><given-names>SE</given-names></name>
<name><surname>Gremmels</surname><given-names>DB</given-names></name>
<name><surname>Keet</surname><given-names>CA</given-names></name>
<etal/></person-group>. <article-title>Neuro- developmental outcome of infants supported with extracorporeal membrane oxygenation after cardiac surgery</article-title>. <source>Pediatrics</source> <year>2003</year>; <volume>111</volume>: <fpage>e671</fpage>–<lpage>675</lpage>.</citation>
</ref>
<ref id="bibr11-0267659112469641">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chorak</surname><given-names>J</given-names></name>
<name><surname>Leader</surname><given-names>I</given-names></name>
<name><surname>Patterson</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Sterility of assembled heart-lung pump beyond 48 hours</article-title>. <source>Am J Infect Control</source> <year>1990</year>; <volume>18</volume>: <fpage>328</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr12-0267659112469641">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Searles</surname><given-names>B</given-names></name>
<name><surname>O’Leary</surname><given-names>CE</given-names></name>
<name><surname>Pettit</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Investigations into the sterility of manually assembled extracorporeal circuits with vented reservoirs</article-title>. <source>J Extra Corpor Technol</source> <year>1999</year>; <volume>31</volume>: <fpage>125</fpage>–<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr13-0267659112469641">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Homishak</surname><given-names>RN</given-names></name>
<name><surname>Widmer</surname><given-names>S</given-names></name>
<name><surname>Klementowich</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Sterility of previously assembled cardiopulmonary bypass circuits</article-title>. <source>J Extra-Corp Tech</source> <year>1993</year>; <volume>25</volume>: <fpage>84</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr14-0267659112469641">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young</surname><given-names>WV</given-names></name>
<name><surname>Heemsoth</surname><given-names>CH</given-names></name>
<name><surname>Georgiafandis</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Extracorporeal circuit sterility after 168 hours</article-title>. <source>J Extra Corpor Technol</source> <year>1997</year>; <volume>29</volume>: <fpage>181</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr15-0267659112469641">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lonský</surname><given-names>V</given-names></name>
<name><surname>Voxová</surname><given-names>B</given-names></name>
<name><surname>Dominik</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>How long can the previously assembled cardiopulmonary bypass circuit stay sterile?</article-title> <source>Acta Medica</source> <year>1998</year>; <volume>41</volume>: <fpage>91</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr16-0267659112469641">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karimova</surname><given-names>A</given-names></name>
<name><surname>Robertson</surname><given-names>A</given-names></name>
<name><surname>Cross</surname><given-names>N</given-names></name>
<etal/></person-group>. <article-title>A wet-primed extracorporeal membrane oxygenation circuit with hollow-fiber membrane oxygenator maintains adequate function for use during cardiopulmonary resuscitation after 2 weeks on standby</article-title>. <source>Crit Care Med</source> <year>2005</year>; <volume>33</volume>: <fpage>1572</fpage>–<lpage>1576</lpage>.</citation>
</ref>
<ref id="bibr17-0267659112469641">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alsoufi</surname><given-names>B</given-names></name>
<name><surname>Al-Radi</surname><given-names>OO</given-names></name>
<name><surname>Nazer</surname><given-names>RI</given-names></name>
<etal/></person-group>. <article-title>Survival outcomes after rescue extracorporeal cardiopulmonary resuscitation in pediatric patients with refractory cardiac arrest</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>2007</year>; <volume>134</volume>: <fpage>952</fpage>–<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr18-0267659112469641">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eriksen</surname><given-names>NH</given-names></name>
<name><surname>Espersen</surname><given-names>F</given-names></name>
<name><surname>Rosdahl</surname><given-names>VT</given-names></name>
<etal/></person-group>. <article-title>Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period</article-title>. <source>Epidemiol Infect</source> <year>1995</year>; <volume>115</volume>: <fpage>51</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr19-0267659112469641">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rais-Bahrami</surname><given-names>K</given-names></name>
<name><surname>Nunez</surname><given-names>S</given-names></name>
<name><surname>Revenis</surname><given-names>ME</given-names></name>
<etal/></person-group>. <article-title>Follow-up study of adolescents exposed to di(2-ethylhexyl) phthalate (DEHP) as neonates on extracorporeal membrane oxygenation (ECMO) support</article-title>. <source>Environ Health Perspect</source> <year>2004</year>; <volume>112</volume>: <fpage>1339</fpage>–<lpage>1340</lpage>.</citation>
</ref>
<ref id="bibr20-0267659112469641">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karle</surname><given-names>VA</given-names></name>
<name><surname>Short</surname><given-names>BL</given-names></name>
<name><surname>Martin</surname><given-names>GR</given-names></name>
<etal/></person-group>. <article-title>Extracorporeal membrane oxygenation exposes infants to the plasticizer, di(2-ethylhexyl)phthalate</article-title>. <source>Crit Care Med</source> <year>1997</year>; <volume>25</volume>: <fpage>696</fpage>–<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr21-0267659112469641">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eig</surname><given-names>M</given-names></name>
<name><surname>Rais-Bahrami</surname><given-names>K</given-names></name>
<name><surname>Soldin</surname><given-names>SJ</given-names></name>
<etal/></person-group>. <article-title>Plasticizer, di(2-ethylhexyl)phthalate (DEHP), exposure in neonatal ECMO vs. near-miss ECMO patients</article-title>. <source>J Neonatal-Perinatal Medicine</source> <year>2012</year>; <volume>3</volume>: <fpage>285</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr22-0267659112469641">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takehisa</surname><given-names>H</given-names></name>
<name><surname>Naokoa</surname><given-names>E</given-names></name>
<name><surname>Masahikoa</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Release behavior of diethylhexyl phthalate from the polyvinyl- chloride tubing used for intravenous administration and the plasticized PVC membrane</article-title>. <source>Int J Pharm</source> <year>2005</year>; <volume>297</volume>(<issue>1–2</issue>): <fpage>30</fpage>–<lpage>37</lpage>.</citation>
</ref></ref-list>
</back>
</article>